DC
ACRS icon

Decheng Capital’s Aclaris Therapeutics ACRS Stock Holding History

Decheng Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.2M Hold
4,041,736
– – 2.29% 4
2025
Q4 		$12.2M Hold
4,041,736
– – 1.64% 9
2025
Q3 		$7.68M Hold
4,041,736
– – 1.34% 10
2025
Q2 		$5.74M Hold
4,041,736
– – 1.45% 11
2025
Q1 		$6.18M Buy
4,041,736
+1,775,069
+78% +$3.79M 1.73% 13
2024
Q4 		$5.62M Buy
+2,266,667
New +$5.64M 1.21% 17

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Decheng Capital's ACRS Position: Q1 2026 in Review

Decheng Capital held its Aclaris Therapeutics (ACRS) position steady in Q1 2026 at 4,041,736 shares worth $15.2M. The position accounts for 2.29% of the portfolio, ranked #4.

Decheng Capital first reported a position in ACRS in Q4 2024 and has held it in 6 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Decheng Capital held 4,041,736 shares of Aclaris Therapeutics worth $15.2M as of Q1 2026.
  • Decheng Capital left its Aclaris Therapeutics share count unchanged in Q1 2026.
  • Aclaris Therapeutics made up 2.29% of Decheng Capital's portfolio in Q1 2026, its #4 holding.
  • Decheng Capital first reported a position in Aclaris Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Decheng Capital's 13F filing for Q1 2026, filed 13 May 2026.